PRESS-RELEASE ·Filed Sep 10, 2026
Press release · Leadership
Actionable Insight • Neutral
Monitor next quarterly earnings for any R&D pipeline updates or product development milestones under the new leadership. The appointment is routine and does not warrant immediate trading action.
Latest settled — T+20d ⚠ clustered
KMTS ▲ +9.33% at T+20d
NEUTRAL call +9.33% · α vs SPY +7.21% · entry $23.57 → $25.77
Latest observation: T+31 +26.30% FF3 residual α
T+1d
-3.05%
call -3.05% · α -3.91%
$22.85
settled 7w ago
T+5d
+3.31%
call +3.31% · α +3.81%
$24.35
settled 6w ago
T+20d
+9.33%
call +9.33% · α +7.21%
$25.77
settled 19d ago
T+60d
Pending
in 5w
Price Chart
Loading chart...
Executive Summary
Kestra Medical Technologies announced the appointment of Daniel Finney as VP of Research & Development, succeeding Phillip Foshee who retired after nearly a decade. This is a routine leadership succession within the R&D organization, with no material financial data or changes to business outlook disclosed.
Key Facts
- Daniel Finney named VP of Research & Development and appointed to executive leadership team
- Finney succeeds Phillip Foshee, who led R&D from 2016 until his recent retirement
- Finney has over 20 years of experience in Class III medical device development, including roles at Stryker, Physio-Control, and Medtronic
- No financial figures, guidance, or business outlook changes were disclosed
Financial Impact
No financial impact disclosed
Risk Factors
- No material risks identified from this filing
Market Snapshot
Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
86% bullish (14 analysts)
Investment Themes
Healthcare & Medical Devices
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3359274 |
18 reports for KMTS
100% Hit rate @ T+20 Went positive at some point 4 of 5 best @ T+20▲ +15.82%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Insider Cluster | $28.76 | awaiting T+20 | — | $28.76 (+0.00%) |
Oct 20, 2026 6d ago | 144 | $27.31 | awaiting T+20 | — | $28.76 (+5.31%) |
Oct 20, 2026 6d ago | ANALYST-UPGRADE | $28.28 | awaiting T+20 | — | $28.76 (+1.70%) |
Sep 30, 2026 26d ago | 144 | $27.12 | awaiting T+20 | — | $28.76 (+6.07%) |
Sep 14, 2026 6w ago | Press Release | $25.18 $26.97 | ▲ +7.11% | ▲ +4.39% | $28.76 (+14.22%) |
Sep 10, 2026 6w ago | Insider Cluster | $22.85 $26.98 | ▲ +18.07% | ▲ +16.21% | $28.76 (+25.86%) |
Sep 10, 2026 6w ago | Press Release | $23.57 $25.77 | ▲ +9.33% | ▲ +7.21% | $28.76 (+22.02%) |
Aug 31, 2026 8w ago | Press Release | $25.12 $28.29 | ▲ +12.62% | ▲ +12.30% | $28.76 (+14.49%) |
Aug 26, 2026 8w ago | Press Release | $26.57 $25.76 | ▼ −3.05% | ▼ −3.27% | $28.76 (+8.24%) |
Aug 11, 2026 10w ago | Insider Cluster | $28.00 $23.57 | ▲ +15.82% | ▲ +13.92% | $28.76 (−2.71%) |
Showing 10 of 18
US Market Status
Market Closed — Opens Wed (13h 19m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers